Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-f54f2e739aebe7aea194141a7163df7a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-f54f2e739aebe7aea194141a7163df7a"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-f54f2e739aebe7aea194141a7163df7a> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mpf54f2e739aebe7aea194141a7163df7a"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mpf54f2e739aebe7aea194141a7163df7a> ) ] ) . # <Composition/composition-en-f54f2e739aebe7aea194141a7163df7a> a fhir:Composition ; fhir:id [ fhir:v "composition-en-f54f2e739aebe7aea194141a7163df7a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-f54f2e739aebe7aea194141a7163df7a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-f54f2e739aebe7aea194141a7163df7a</b></p><a name=\"composition-en-f54f2e739aebe7aea194141a7163df7a\"> </a><a name=\"hccomposition-en-f54f2e739aebe7aea194141a7163df7a\"> </a><a name=\"composition-en-f54f2e739aebe7aea194141a7163df7a-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/214/001-005</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - kinzalkomb</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/02/214/001-005" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mpf54f2e739aebe7aea194141a7163df7a" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - kinzalkomb"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Kinzalkomb is and what it is used for</li><li>What you need to know before you take Kinzalkomb</li><li>How to take Kinzalkomb</li><li>Possible side effects</li><li>How to store Kinzalkomb</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What kinzalkomb is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What kinzalkomb is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"kinzalkomb-is-a-combination-of-two-active-substances-telmisartan-and-hydrochlorothiazide-in-one-tablet-both-of-these-substances-help-to-control-high-blood-pressure\">Kinzalkomb is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet. Both of these substances help to control high blood pressure.</h2><h2 id=\"telmisartan-belongs-to-a-group-of-medicines-called-angiotensin-ii-receptor-antagonists-angiotensin-ii-is-a-substance-produced-in-your-body-which-causes-your-blood-vessels-to-narrow-thus-increasing-your-blood-pressure-telmisartan-blocks-the-effect-of-angiotensin-ii-so-that-the-blood-vessels-relax-and-your-blood-pressure-is-lowered\">Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin-II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.</h2><p>Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure. High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range. Kinzalkomb is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take kinzalkomb" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take kinzalkomb" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Kinzalkomb</p><p>if you are allergic to telmisartan or any of the other ingredients of this medicine (listed in section 6).</p><p>if you are allergic to hydrochlorothiazide or to any other sulfonamide-derived medicines.</p><p>if you are more than 3 months pregnant. (It is also better to avoid Kinzalkomb in early pregnancy see pregnancy section.)</p><p>if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.</p><p>if you have severe kidney disease.</p><p>if your doctor determines that you have low potassium levels or high calcium levels in your blood that do not get better with treatment.</p><h2 id=\"if-you-have-diabetes-or-impaired-kidney-function-and-you-are-treated-with-a-blood-pressure-lowering-medicine-containing-aliskiren-if-any-of-the-above-applies-to-you-tell-your-doctor-or-pharmacist-before-taking-kinzalkomb-warnings-and-precautions-talk-to-your-doctor-before-taking-kinzalkomb-if-you-are-suffering-or-have-ever-suffered-from-any-of-the-following-conditions-or-illnesses\">if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. If any of the above applies to you, tell your doctor or pharmacist before taking Kinzalkomb. Warnings and precautions Talk to your doctor before taking Kinzalkomb if you are suffering or have ever suffered from any of the following conditions or illnesses:</h2><h2 id=\"low-blood-pressure-hypotension-likely-to-occur-if-you-are-dehydrated-excessive-loss-of-body-water-or-have-salt-deficiency-due-to-diuretic-therapy-water-tablets-low-salt-diet-diarrhoea-vomiting-or-haemodialysis\">Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (water tablets), low-salt diet, diarrhoea, vomiting, or haemodialysis.</h2><h2 id=\"kidney-disease-or-kidney-transplant\">Kidney disease or kidney transplant.</h2><h2 id=\"renal-artery-stenosis-narrowing-of-the-blood-vessels-to-one-or-both-kidneys\">Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).</h2><h2 id=\"liver-disease\">Liver disease.</h2><h2 id=\"heart-trouble\">Heart trouble.</h2><h2 id=\"diabetes\">Diabetes.</h2><h2 id=\"gout\">Gout.</h2><h2 id=\"raised-aldosterone-levels-water-and-salt-retention-in-the-body-along-with-imbalance-of-various-blood-minerals\">Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).</h2><h2 id=\"systemic-lupus-erythematosus-also-called-lupus-or-sle--a-disease-where-the-body-s-immune-system-attacks-the-body\">Systemic lupus erythematosus (also called lupus or SLE ) a disease where the body s immune system attacks the body.</h2><h2 id=\"the-active-ingredient-hydrochlorothiazide-can-cause-an-unusual-reaction-resulting-in-a-decrease-in-vision-and-eye-pain-these-could-be-symptoms-of-fluid-accumulation-in-the-vascular-layer-of-the-eye-choroidal-effusion-or-an-increase-of-pressure-in-your-eye-and-can-happen-within-hours-to-weeks-of-taking-kinzalkomb-this-can-lead-to-permanent-vision-impairment-if-not-treated\">The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking Kinzalkomb. This can lead to permanent vision impairment, if not treated.</h2><p>If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Kinzalkomb. Talk to your doctor before taking Kinzalkomb:</p><p>if you are taking any of the following medicines used to treat high blood pressure:</p><ul><li>an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</li><li>aliskiren. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading Do not take Kinzalkomb .</li></ul><p>if you are taking digoxin.</p><h2 id=\"if-you-experienced-breathing-or-lung-problems-including-inflammation-or-fluid-in-the-lungs-following-hydrochlorothiazide-intake-in-the-past-if-you-develop-any-severe-shortness-of-breath-or-difficulty-breathing-after-taking-kinzalkomb-seek-medical-attention-immediately-you-must-tell-your-doctor-if-you-think-you-are-or-might-become-pregnant-kinzalkomb-is-not-recommended-in-early-pregnancy-and-must-not-be-taken-if-you-are-more-than-3-months-pregnant-as-it-may-cause-serious-harm-to-your-baby-if-used-at-that-stage-see-pregnancy-section-treatment-with-hydrochlorothiazide-may-cause-electrolyte-imbalance-in-your-body-typical-symptoms-of-fluid-or-electrolyte-imbalance-include-dry-mouth-weakness-lethargy-drowsiness-restlessness-muscle-pain-or-cramps-nausea-feeling-sick-vomiting-tired-muscles-and-an-abnormally-fast-heart-rate-faster-than-100-beats-per-minute-if-you-experience-any-of-these-you-should-tell-your-doctor-you-should-also-tell-your-doctor-if-you-experience-an-increased-sensitivity-of-the-skin-to-the-sun-with-symptoms-of-sunburn-such-as-redness-itching-swelling-blistering-occurring-more-quickly-than-normal-in-case-of-surgery-or-anaesthetics-you-should-tell-your-doctor-that-you-are-taking-kinzalkomb-kinzalkomb-may-be-less-effective-in-lowering-the-blood-pressure-in-black-patients-children-and-adolescents-the-use-of-kinzalkomb-in-children-and-adolescents-up-to-the-age-of-18-years-is-not-recommended-other-medicines-and-kinzalkomb-tell-your-doctor-or-pharmacist-if-you-are-taking-have-recently-taken-or-might-take-any-other-medicines-your-doctor-may-need-to-change-the-dose-of-these-other-medications-or-take-other-precautions-in-some-cases-you-may-have-to-stop-taking-one-of-the-medicines-this-applies-especially-to-the-medicines-listed-below-taken-at-the-same-time-with-kinzalkomb\">if you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking Kinzalkomb, seek medical attention immediately. You must tell your doctor if you think you are (or might become) pregnant. Kinzalkomb is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). Treatment with hydrochlorothiazide may cause electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, nausea (feeling sick), vomiting, tired muscles, and an abnormally fast heart rate (faster than 100 beats per minute). If you experience any of these you should tell your doctor. You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal. In case of surgery or anaesthetics, you should tell your doctor that you are taking Kinzalkomb. Kinzalkomb may be less effective in lowering the blood pressure in black patients. Children and adolescents The use of Kinzalkomb in children and adolescents up to the age of 18 years is not recommended. Other medicines and Kinzalkomb Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medications or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with Kinzalkomb:</h2><h2 id=\"lithium-containing-medicines-to-treat-some-types-of-depression\">Lithium containing medicines to treat some types of depression.</h2><h2 id=\"medicines-associated-with-low-blood-potassium-hypokalaemia-such-as-other-diuretics-water-tablets-laxatives-eg-castor-oil-corticosteroids-eg-prednisone-acth-a-hormone-amphotericin-an-antifungal-medicine-carbenoxolone-used-to-treat-mouth-ulcers-penicillin-g-sodium-an-antibiotic-and-salicylic-acid-and-derivatives\">Medicines associated with low blood potassium (hypokalaemia) such as other diuretics, ('water tablets'), laxatives (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.</h2><h2 id=\"medicines-that-may-increase-blood-potassium-levels-such-as-potassium-sparing-diuretics-potassium-supplements-salt-substitutes-containing-potassium-ace-inhibitors-cyclosporin-an-immunosuppressant-medicine-and-other-medicinal-products-such-as-heparin-sodium-an-anticoagulant\">Medicines that may increase blood potassium levels such as potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors cyclosporin (an immunosuppressant medicine) and other medicinal products such as heparin sodium (an anticoagulant)..</h2><h2 id=\"medicines-that-are-affected-by-changes-of-the-blood-potassium-level-such-as-heart-medicines-eg-digoxin-or-medicines-to-control-the-rhythm-of-your-heart-eg-quinidine-disopyramide-amiodarone-sotalol-medicines-used-for-mental-disorders-eg-thioridazine-chlorpromazine-levomepromazine-and-other-medicines-such-as-certain-antibiotics-eg-sparfloxacine-pentamidine-or-certain-medicines-to-treat-allergic-reactions-eg-terfenadine\">Medicines that are affected by changes of the blood potassium level such as heart medicines (e.g. digoxin) or medicines to control the rhythm of your heart (e.g. quinidine, disopyramide, amiodarone, sotalol), medicines used for mental disorders (e.g. thioridazine, chlorpromazine, levomepromazine) and other medicines such as certain antibiotics (e.g. sparfloxacine, pentamidine) or certain medicines to treat allergic reactions (e.g. terfenadine).</h2><h2 id=\"medicines-for-the-treatment-of-diabetes-insulins-or-oral-agents-such-as-metformin\">Medicines for the treatment of diabetes (insulins or oral agents such as metformin).</h2><h2 id=\"cholestyramine-and-colestipol-medicines-for-lowering-blood-fat-levels\">Cholestyramine and colestipol, medicines for lowering blood fat levels.</h2><h2 id=\"medicines-to-increase-blood-pressure-such-as-noradrenaline-\">Medicines to increase blood pressure, such as noradrenaline .</h2><h2 id=\"muscle-relaxing-medicines-such-as-tubocurarine\">Muscle relaxing medicines, such as tubocurarine.</h2><h2 id=\"calcium-supplements-andor-vitamin-d-supplements\">Calcium supplements and/or vitamin D supplements.</h2><h2 id=\"anti-cholinergic-medicines-medicines-used-to-treat-a-variety-of-disorders-such-as-gastrointestinal-cramps-urinary-bladder-spasm-asthma-motion-sickness-muscular-spasms-parkinsons-disease-and-as-an-aid-to-anaesthesia-such-as-atropine-and-biperiden\">Anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia) such as atropine and biperiden.</h2><h2 id=\"amantadine-medicine-used-to-treat-parkinson-s-disease-and-also-used-to-treat-or-prevent-certain-illnesses-caused-by-viruses\">Amantadine (medicine used to treat Parkinson s disease and also used to treat or prevent certain illnesses caused by viruses).</h2><h2 id=\"other-medicines-used-to-treat-high-blood-pressure-corticosteroids-painkillers-such-as-non--steroidal-anti-inflammatory-drugs-nsaids-medicines-to-treat-cancer-gout-or-arthritis\">Other medicines used to treat high blood pressure, corticosteroids, painkillers (such as non- steroidal anti-inflammatory drugs [NSAIDs]), medicines to treat cancer, gout, or arthritis.</h2><h2 id=\"if-you-are-taking-an-ace-inhibitor-or-aliskiren-see-also-information-under-the-headings-do-not-take-kinzalkomb-and-warnings-and-precautions-\">If you are taking an ACE-inhibitor or aliskiren (see also information under the headings Do not take Kinzalkomb and Warnings and precautions ).</h2><p>Digoxin. Kinzalkomb may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking Kinzalkomb. The effect of Kinzalkomb may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen). Kinzalkomb with food and alcohol You can take Kinzalkomb with or without food. Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint. Pregnancy and breast-feeding Pregnancy You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Kinzalkomb before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Kinzalkomb. Kinzalkomb is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Kinzalkomb is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed. Driving and using machines Some people feel dizzy or tired when taking Kinzalkomb. If you feel dizzy or tired, do not drive or operate machinery. Kinzalkomb contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free . Kinzalkomb contains milk sugar (lactose) If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Kinzalkomb contains sorbitol This medicine contains 169 mg sorbitol in each tablet.</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take kinzalkomb" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take kinzalkomb" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one tablet a day. Try to take a tablet at the same time each day. You can take Kinzalkomb with or without food. The tablets should be swallowed with some water or other non-alcoholic drink. It is important that you take Kinzalkomb every day until your doctor tells you otherwise. If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day. If you take more Kinzalkomb than you should If you accidentally take too many tablets you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, reduced kidney function including kidney failure, have also been reported. Due to the hydrochlorothiazide component, markedly low blood pressure and low blood levels of potassium can also happen, which may result in nausea, sleepiness and muscle cramps and/or irregular heartbeat associated with the concomitant use of medicines such as digitalis or certain anti-arrhythmic treatments. Contact your doctor, pharmacist, or your nearest hospital emergency department immediately. If you forget to take Kinzalkomb If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses. If you have further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some side effects can be serious and need immediate medical attention: You should see your doctor immediately if you experience any of the following symptoms: Sepsis* (often called \"blood poisoning\", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema), blistering and peeling of the top layer of skin (toxic epidermal necrolysis; these side effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal. Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for Kinzalkomb. Possible side effects of Kinzalkomb: Common side effects (may affect up to 1 in 10 people) Dizziness Uncommon side effects (may affect up to 1 in 100 people) Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels. Rare side effects (may affect up to 1 in 1,000 people) Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body s immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses, feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood. Adverse reactions reported with one of the individual components may be potential adverse reactions with Kinzalkomb, even if not observed in clinical trials with this product.<br/>Telmisartan In patients taking telmisartan alone the following additional side effects have been reported: Uncommon side effects (may affect up to 1 in 100 people) Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, deficiency in red blood cells (anaemia), high potassium levels, slow heart rate (bradycardia), cough, kidney impairment including acute kidney failure, weakness. Rare side effects (may affect up to 1 in 1,000 people) Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction, drug rash), low blood sugar levels (in diabetic patients), somnolence, upset stomach, eczema (a skin disorder), arthrosis, inflammation of the tendons, decreased haemoglobin (a blood protein). Very rare side effects (may affect up to 1 in 10,000 people) Progressive scarring of lung tissue (interstitial lung disease) ** * The event may have happened by chance or could be related to a mechanism currently not known. ** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. However, it is not known whether telmisartan was the cause. Hydrochlorothiazide In patients taking hydrochlorothiazide alone the following additional side effects have been reported: Common side effects (may affect up to 1 in 10 people) Feeling sick (nausea), low blood magnesium level. Rare side effects (may affect up to 1 in 1,000 people) Reduction in blood platelets, which increases risk of bleeding or bruising (small purple-red marks in skin or other tissue caused by bleeding), high blood calcium level, headache. Very rare side effects (may affect up to 1 in 10,000 people) Increased pH (disturbed acid-base balance) due to low blood chloride level, acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion). Not known (frequency cannot be estimated from the available data) Inflammation of the salivary gland, skin and lip cancer (non-melanoma skin cancer), decreases in the number (or even lack) of cells in the blood, including low red and white blood cell count, serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light-headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body s immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased blood levels of glucose, difficulties in controlling blood/ urine levels of glucose in patients with a diagnosis of diabetes mellitus, or fat in the blood. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store kinzalkomb" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store kinzalkomb" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton after EXP . The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture. Remove your Kinzalkomb tablet from the blister only directly prior to intake. Occasionally, the outer layer of the blister pack separates from the inner layer between the blister pockets. You do not need to take any action if this happens. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Kinzalkomb contains</p><p>The active substances are telmisartan and hydrochlorothiazide. Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide.</p><p>The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, red iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420) What Kinzalkomb looks like and contents of the pack Kinzalkomb 40 mg/12.5 mg tablets are red and white, oblong-shaped two-layer tablets engraved with the code number 'H4'. Kinzalkomb is available in blisters packs containing 14, 28, 56, or 98 tablets, or unit dose blister packs containing 28 x 1 tablets. Not all pack sizes may be available in your country. Marketing Authorisation Holder Bayer AG 51368 Leverkusen Germany Manufacturer Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. Belgi / Belgique / Belgien Bayer SA-NV T l/Tel: +32-(0)2-535 63 Lietuva UAB Bayer Tel. +37 05 23 36</p><p>. +359 (0)2-424 72 Luxembourg / Luxemburg Bayer SA-NV T l/Tel: +32-(0)2-535 63 esk republika Bayer s.r.o. Tel: +420 266-101-Magyarorsz g Bayer Hung ria Kft. Tel.:+36-14 87-41 Danmark Bayer A/S Tlf: +45-45 23 50 Malta Alfred Gera and Sons Ltd. Tel: +356-21 44 62 Deutschland Bayer Vital GmbH Tel: +49-(0)214-30 513 Nederland Bayer B.V. Tel: +31-(0)297-28 06 Eesti Bayer O Tel: +372 655 85 Norge Bayer AS Tlf. +47 23 13 05<br/>Bayer<br/>: +30 210 618 75 sterreich Bayer Austria Ges. m. b. H. Tel: +43-(0)1-711 46-0 Espa a Bayer Hispania S.L. Tel: +34-93-495 65 Polska Bayer Sp. z o.o. Tel.: +48-22-572 35 France Bayer HealthCare T l (N vert): +33-(0)800 87 54 Portugal Bayer Portugal Lda Tel: +351-21-416 42 Hrvatska Bayer d.o.o. Tel: + 385-(0)1-6599 Rom nia SC Bayer SRL Tel.: +40 21 528 59 Ireland Bayer Limited Tel: +353-1-216-3Slovenija Bayer d. o. o. Tel.: +386-1-58 14 sland Icepharma hf. S mi: +354 540 8Slovensk republika Bayer, spol. s r.o. Tel: +421 2 59 21 31 Italia Bayer S.p.A. Tel: +39-02-397 Suomi/Finland Bayer Oy Puh/Tel.: +358-20 785<br/>NOVAGEM Limited : + 357 22 48 38 Sverige Bayer AB Tel: +46-(0)8-580 223 Latvija SIA Bayer Tel: +371 67 84 55 United Kingdom (Northern Ireland) Bayer AG Tel: +44 (0) 118 206 30 This leaflet was last revised in {MM/YYYY} Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mpf54f2e739aebe7aea194141a7163df7a> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mpf54f2e739aebe7aea194141a7163df7a"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpf54f2e739aebe7aea194141a7163df7a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpf54f2e739aebe7aea194141a7163df7a</b></p><a name=\"mpf54f2e739aebe7aea194141a7163df7a\"> </a><a name=\"hcmpf54f2e739aebe7aea194141a7163df7a\"> </a><a name=\"mpf54f2e739aebe7aea194141a7163df7a-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/214/001-005</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Kinzalkomb 40 mg/12.5 mg tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/02/214/001-005" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "Kinzalkomb 40 mg/12.5 mg tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
